Eikon Therapeutics, Inc. (EIKN) stock
EIKNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$5.15−0.23 (-4.36%)
Close on Nov 17, 2026Market cap $278.95MP/E –Yield –
Eikon Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $75.46M | – |
| Q1 FY2026 | Mar 31, 2026 | $70.05M | – |
| Q2 FY2025 | Jun 30, 2025 | $69.19M | – |
| Q1 FY2025 | Mar 31, 2025 | $56.59M | – |
See a number that looks wrong?